PDS Biotech prices up to USD 22.55 million PIPE led by Nant Capital

• PDS Biotech announced a PIPE financing of up to USD 22.55 million led by Nant Capital, with additional participation from existing investors.
• Initial closing targets about USD 11.55 million around Sept. 11, 2026, via unregistered common stock or pre-funded warrants with common warrants.
• Units priced at USD 0.28 per share unit or USD 0.28 per pre-funded unit.
• Milestone closing would add USD 11 million if a registrational Phase 3 PDS0301 protocol is submitted to the FDA in collaboration with Nant.
• Nant can appoint two directors if it owns at least 15%, including Patrick Soon-Shiong; proceeds earmarked for debt repayment, R&D, working capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080830PRIMZONEFULLFEED9822558) on September 08, 2026, and is solely responsible for the information contained therein.